Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Bioequivalence: Overview01:16

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of a transmembrane-activating STING agonist using genetically humanized mice.

Cell reports·2026
Same author

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

JACC. CardioOncology·2026
Same author

Comparison of Cefdinir and Cephalexin as Step-Down Therapy in Pyelonephritis or Urosepsis.

Journal of pharmacy practice·2025
Same author

In silico discovery and mechanistic profiling of STING agonists engaging the transmembrane domain.

European journal of medicinal chemistry·2025
Same author

Characterization of a Novel Transmembrane Activating STING Agonist using Genetically Humanized Mice.

bioRxiv : the preprint server for biology·2025
Same author

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.

Blood·2025
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
14:13

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory

Published on: January 1, 2018

Postgraduate year one pharmacy residency program equivalency.

, Ché J Jordan, Geoffrey C Wall

    Pharmacotherapy
    |December 2, 2009
    PubMed
    Summary
    This summary is machine-generated.

    The American College of Clinical Pharmacy (ACCP) established a task force to define pharmacist residency equivalency. This process allows experienced practitioners to demonstrate skills equivalent to formal residency training.

    More Related Videos

    Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience
    10:17

    Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience

    Published on: November 15, 2024

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
    14:13

    Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory

    Published on: January 1, 2018

    Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience
    10:17

    Improving Student Outcomes with an Adaptable Molecular Cloning Course-Based Undergraduate Research Experience

    Published on: November 15, 2024

    Area of Science:

    • Pharmacy Practice
    • Pharmacist Professional Development
    • Continuing Education

    Background:

    • The American College of Clinical Pharmacy (ACCP) initiated a task force in 2006 to address the need for defining pharmacist residency equivalency.
    • There is a growing trend towards residency training as a prerequisite for pharmacists providing direct patient care.

    Purpose of the Study:

    • To define the professional experience required for a clinically mature practitioner to meet or exceed the knowledge and skills of an accredited postgraduate year one (PGY1) residency-trained pharmacist.
    • To lay the foundation for establishing a residency equivalency process.

    Main Methods:

    • The task force discussed qualitative and quantitative components of documentation using a residency equivalency portfolio.
    • Consideration of potential roles for academia, professional organizations, and employers in the equivalency process.
    • Identification of possible barriers to implementing an equivalency process.

    Main Results:

    • The commentary outlines the framework for a residency equivalency portfolio, detailing necessary documentation.
    • Identified key stakeholders and their potential roles in facilitating the equivalency process.
    • Acknowledged potential challenges and barriers that may impede the establishment of a formal equivalency pathway.

    Conclusions:

    • A residency equivalency process can promote the growth and development of existing and future residency programs.
    • Qualified practitioners can demonstrate their capabilities through a defined equivalency process, validating their experience.
    • The ACCP encourages collaborative efforts among stakeholders to support the transition towards residency training as a standard for direct patient care pharmacists.